Stephens Reiterates Overweight Rating for MaxCyte (NASDAQ:MXCT)

Stephens reaffirmed their overweight rating on shares of MaxCyte (NASDAQ:MXCT – Free Report) in a report published on Tuesday, Benzinga reports. The firm currently has a $11.00 price target on the stock. Several other equities analysts have also recently weighed in on the company. BTIG Research lowered their price target on MaxCyte from $10.00 to […]

Related Keywords

China ,United States ,William Blair ,China Universal Asset Management Co ,Financial Services Group Inc ,Maxcyte Inc ,Nisa Investment Advisors ,Victory Capital Management Inc ,Johnson Investment Counsel Inc ,Free Report ,Get Free Report ,Services Group ,Capital Management ,Investment Counsel ,Investment Advisors ,China Universal Asset Management ,Universal Asset Management ,Maxcyte Daily ,Maxcyte ,Nasdaq Mxct ,Mxct ,Medical ,Reiterated Rating ,Stephens ,